MedTrace Logo

Vortioxetine in Patients With Depression and Early Dementia

NCT04294654 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2022-08-08

No results posted yet for this study

Summary

This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia

Conditions

Interventions

DRUG

Vortioxetine

Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.

Sponsors & Collaborators

  • ICON plc

    collaborator INDUSTRY

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2022-07-06
Completion
2022-07-20

Countries

  • Estonia
  • France
  • Italy
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04294654 on ClinicalTrials.gov